Biological E

Two major vaccine makers from Hyderabad, Biological E Ltd and Bharat Biotech, together are holding about 250 million doses of COVID-19 vaccines ready to dispatch as and when orders are received.

Hyderabad-based pharmaceutical and vaccine manufacturer Biological E Limited (BE), on Friday announced that its 14-valent paediatric Pneumococcal Conjugate Vaccine has received approval for manufacture and commercialisation in India.

Biological E. Ltd (BE) on Thursday said it has delivered 10 crore (100 million) doses of its COVID-19 vaccine, Corbevax, to the Centre so far.

The government on Wednesday approved Biological E's Corbevax as a precaution dose for those above 18 years fully vaccinated with either Covishield or Covaxin.

Biological E's COVID-19 vaccine Corbevax has been cleared for booster shot for those 18 and above.

Pharmaceuticals firm Biological E today said it has reduced the price of its COVID-19 vaccine Corbevax to Rs 250 from Rs 840 a dose, inclusive of goods and services tax, for private vaccination centres.

Mahima Datla, the MD of Biological E -- whose vaccine Corbevax was launched today for 12-to 14-year-olds in the country -- today indicated that the affordability of her vaccine was one of the key goals they worked for.

Mahima Datla, Managing Director of Biological E Ltd., is speaking to NDTV as India today started the vaccination of children aged 12 to 14 years.

The Corbevax COVID-19 vaccine for those aged 12 to 14 will cost Rs 800 in the market before taxes, sources have said. It will be sold to the government at Rs 145, the lowest in the world.

A second COVID-19 vaccine for children has received emergency use authorisation in India. Biological E Ltd's Corbevax has got EUA for children and teens between 12 and 18 years, the vaccine-maker said in a statement today.

An expert panel of the country's central drug authority on Monday recommended granting restricted emergency use authorisation to Biological E'sCOVID-19 vaccine, Corbevax, for age group 12 to 18 years subject to certain conditions, sources said.

The first batch of COVID-19 vaccines that are part of the Quad group of countries' pledge to donate shots across the world, manufactured by India's Biological E, will roll out in the first half of 2022, the grouping said in a statement on Friday.

Biological E. Limited plans to complete production at a rate of 75 million doses of its COVID-19 vaccine Corbevax per month, anticipating over 100 million doses per month from February 2022.

The Texas-India vaccine diplomacy, a collaboration for shared global health between Indian pharmaceutical company Biological E and the Texas Children''s Hospital and Baylor College of Medicine, has led to the development of a cost-efficient vaccine

The United States and India's Biological E. Ltd said on Monday they had finalised a financing arrangement for $50 million to expand the vaccine maker's capacity to produce COVID-19 shots.

Two major vaccine makers from Hyderabad, Biological E Ltd and Bharat Biotech, together are holding about 250 million doses of COVID-19 vaccines ready to dispatch as and when orders are received.

Hyderabad-based pharmaceutical and vaccine manufacturer Biological E Limited (BE), on Friday announced that its 14-valent paediatric Pneumococcal Conjugate Vaccine has received approval for manufacture and commercialisation in India.

Biological E. Ltd (BE) on Thursday said it has delivered 10 crore (100 million) doses of its COVID-19 vaccine, Corbevax, to the Centre so far.

The government on Wednesday approved Biological E's Corbevax as a precaution dose for those above 18 years fully vaccinated with either Covishield or Covaxin.

Biological E's COVID-19 vaccine Corbevax has been cleared for booster shot for those 18 and above.

Pharmaceuticals firm Biological E today said it has reduced the price of its COVID-19 vaccine Corbevax to Rs 250 from Rs 840 a dose, inclusive of goods and services tax, for private vaccination centres.

Mahima Datla, the MD of Biological E -- whose vaccine Corbevax was launched today for 12-to 14-year-olds in the country -- today indicated that the affordability of her vaccine was one of the key goals they worked for.

Mahima Datla, Managing Director of Biological E Ltd., is speaking to NDTV as India today started the vaccination of children aged 12 to 14 years.

The Corbevax COVID-19 vaccine for those aged 12 to 14 will cost Rs 800 in the market before taxes, sources have said. It will be sold to the government at Rs 145, the lowest in the world.

A second COVID-19 vaccine for children has received emergency use authorisation in India. Biological E Ltd's Corbevax has got EUA for children and teens between 12 and 18 years, the vaccine-maker said in a statement today.

An expert panel of the country's central drug authority on Monday recommended granting restricted emergency use authorisation to Biological E'sCOVID-19 vaccine, Corbevax, for age group 12 to 18 years subject to certain conditions, sources said.

The first batch of COVID-19 vaccines that are part of the Quad group of countries' pledge to donate shots across the world, manufactured by India's Biological E, will roll out in the first half of 2022, the grouping said in a statement on Friday.

Biological E. Limited plans to complete production at a rate of 75 million doses of its COVID-19 vaccine Corbevax per month, anticipating over 100 million doses per month from February 2022.

The Texas-India vaccine diplomacy, a collaboration for shared global health between Indian pharmaceutical company Biological E and the Texas Children''s Hospital and Baylor College of Medicine, has led to the development of a cost-efficient vaccine

The United States and India's Biological E. Ltd said on Monday they had finalised a financing arrangement for $50 million to expand the vaccine maker's capacity to produce COVID-19 shots.